Market Research Report
Hyperphosphatemia - Pipeline Review, H1 2020
|Hyperphosphatemia - Pipeline Review, H1 2020|
Published: June 30, 2020
Global Markets Direct
Content info: 80 Pages
Delivery time: 1-2 business days
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hyperphosphatemia - Pipeline Review, H1 2020, provides an overview of the Hyperphosphatemia (Nutritional Disorders) pipeline landscape.
Hyperphosphatemia, that is, abnormally high serum phosphate levels, can result from increased phosphate intake, decreased phosphate excretion, or a disorder that shifts intracellular phosphate to extracellular space. This condition is most commonly seen in patients with chronic kidney disease. Signs and symptoms include fatigue, nausea, sleep disturbances, shortness of breath, bone and joint pain, pruritus and rash. Treatment includes phosphate binders and diuretics.
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hyperphosphatemia - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Hyperphosphatemia (Nutritional Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Hyperphosphatemia (Nutritional Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hyperphosphatemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 2, 1, 1, 3 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.
Hyperphosphatemia (Nutritional Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.